Position in NXTC
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,582,701
-$926,400 QoQ
Shares Held
241,826
-2.2% QoQ
Ownership
6.69%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NXTC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Affinity Asset Advisors, LLC holds $1,518,254,571 across 81 Biotechnology names. NXTC ranks #68 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
1,284,926 | $108,152,221 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
1,675,000 | $97,401,250 | |
| 3 | ERAS |
Erasca, Inc.
|
5,350,000 | $86,563,000 | |
| 4 | INSM |
INSMED Inc
|
480,000 | $78,489,600 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
2,800,000 | $77,560,000 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,279,134 | $64,519,518 | |
| 7 | CNTA |
Centessa Pharmaceuticals plc
|
1,400,000 | $55,608,000 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
170,000 | $54,772,300 |
All Filings in NXTC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,582,701 | 241,826 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $3,509,101 | 247,294 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,124,428 | 191,882 | Shares | Sole | 2025-11-14 | |
| 2025-09-30 | $1,124,428 | 191,882 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||